Explore the words cloud of the DYS_FUNCTION project. It provides you a very rough idea of what is the project "DYS_FUNCTION" about.
The following table provides information about the project.
Coordinator |
UNIVERSITY COLLEGE LONDON
Organization address contact info |
Coordinator Country | United Kingdom [UK] |
Project website | http://www.ucl.ac.uk/ich/research/developmental-neurosciences/molecular-neurosciences/dubowitz-neuromuscular-centre |
Total cost | 195˙454 € |
EC max contribution | 195˙454 € (100%) |
Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
Code Call | H2020-MSCA-IF-2014 |
Funding Scheme | MSCA-IF-EF-RI |
Starting year | 2016 |
Duration (year-month-day) | from 2016-01-01 to 2017-12-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | UNIVERSITY COLLEGE LONDON | UK (London) | coordinator | 195˙454.00 |
Duchenne muscular dystrophy (DMD) stems from loss of dystrophin in skeletal and cardiac muscles, which leads to loss of ambulation and cardio-respiratory failure. The most promising treatment that could be applicable to 83% of DMD patients is exon skipping, a technology where the EU is a world leader. Antisense oligonucleotide mediated exon skipping targets DMD pre-mRNA to induce skipping of specific exons and restore the open reading frame. This allows expression of shorter dystrophin proteins that lack domains encoded by the skipped exon(s). A crucial question is how to predict which short dystrophins will be stable and functional. This knowledge is fundamental to select DMD patients that would most benefit from this treatment and identify exons worth targeting via exon skipping. The goal of this proposal is to develop a new use of exon skipping technology to rapidly generate mouse models to screen short dystrophins for in vivo stability and functionality in both skeletal and cardiac muscles. This is made possible by a new exon skipping chemistry developed in the UK with unparalleled skipping efficiency in vivo and capable of targeting the heart. I will use this technology to create mouse models for two short dystrophins generated in DMD patients undergoing exon 51 skipping in the current UK clinical trial. I will then biochemically assess their stability and functionality in limb, cardiac and respiratory muscles. Parallel histological studies will assess the presence of muscle pathology with a focus on heart and diaphragm that cannot be sampled in DMD patients. This project will serve as a trampoline for future studies to identify dystrophin exons that when skipped will produce functional proteins with clinical benefits. In addition, this research will generate new fundamental knowledge on dystrophin domains critical for muscle function and may help in the prognosis of DMD patients currently undergoing exon 51 skipping.
year | authors and title | journal | last update |
---|---|---|---|
2018 |
Nalinda B Wasala, Jin-Hong Shin, Yi Lai, Yongping Yue, Federica Montanaro, Dongsheng Duan Cardiac specific expression of ∆H2-R15 mini-dystrophin normalized all ECG abnormalities and the end-diastolic volume in a 23-m-old mouse model of Duchenne dilated cardiomyopathy published pages: , ISSN: 1043-0342, DOI: 10.1089/hum.2017.144 |
Human Gene Therapy | 2019-06-14 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DYS_FUNCTION" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "DYS_FUNCTION" are provided by the European Opendata Portal: CORDIS opendata.